BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 22377738)

  • 1. Rituximab in immunologic glomerular diseases.
    Ejaz AA; Asmar A; Alsabbagh MM; Ahsan N
    MAbs; 2012; 4(2):198-207. PubMed ID: 22377738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab in pediatric renal transplantation: a treatment for allograft rejection with B-cell infiltrates?
    Zand MS
    Am J Transplant; 2008 Dec; 8(12):2489-90. PubMed ID: 19032220
    [No Abstract]   [Full Text] [Related]  

  • 3. Rituximab-based novel strategies for the treatment of immune-mediated glomerular diseases.
    Kattah AG; Fervenza FC; Roccatello D
    Autoimmun Rev; 2013 Jun; 12(8):854-9. PubMed ID: 23000633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficient B cell Depletion With Rituximab Despite Massive Proteinuria.
    Halfon M; Pascual M; Aubert V; Rotman S; Yannick MD
    Transplantation; 2018 Oct; 102(10):e401-e402. PubMed ID: 29965953
    [No Abstract]   [Full Text] [Related]  

  • 5. Rationale and design of the RIACT-study: a multi-center placebo controlled double blind study to test the efficacy of RItuximab in Acute Cellular tubulointerstitial rejection with B-cell infiltrates in renal Transplant patients: study protocol for a randomized controlled trial.
    Schiffer L; Schiffer M; Merkel S; Schwarz A; Mengel M; Jürgens C; Schroeder C; Zoerner AA; Püllmann K; Bröcker V; Becker JU; Dämmrich ME; Träder J; Grosshennig A; Biertz F; Haller H; Koch A; Gwinner W
    Trials; 2012 Oct; 13():199. PubMed ID: 23101480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update on the role of rituximab in kidney diseases and transplant.
    Ramanath V; Nistala R; Chaudhary K
    Expert Opin Biol Ther; 2012 Feb; 12(2):223-33. PubMed ID: 22188359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, prospective trial of rituximab for acute rejection in pediatric renal transplantation.
    Zarkhin V; Li L; Kambham N; Sigdel T; Salvatierra O; Sarwal MM
    Am J Transplant; 2008 Dec; 8(12):2607-17. PubMed ID: 18808404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longitudinal analysis of T and B cell phenotype and function in renal transplant recipients with or without rituximab induction therapy.
    Kamburova EG; Koenen HJ; van den Hoogen MW; Baas MC; Joosten I; Hilbrands LB
    PLoS One; 2014; 9(11):e112658. PubMed ID: 25393622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Rationale and clinical evidence for the use of rituximab in glomerular diseases].
    Mani LY; Vogt B; Burnier M; Golshayan D
    Rev Med Suisse; 2011 Apr; 7(290):819-24. PubMed ID: 21595313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab in severe lupus nephritis: early B-cell depletion affects long-term renal outcome.
    Melander C; Sallée M; Trolliet P; Candon S; Belenfant X; Daugas E; Rémy P; Zarrouk V; Pillebout E; Jacquot C; Boffa JJ; Karras A; Masse V; Lesavre P; Elie C; Brocheriou I; Knebelmann B; Noël LH; Fakhouri F
    Clin J Am Soc Nephrol; 2009 Mar; 4(3):579-87. PubMed ID: 19261822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug insight: rituximab in renal disease and transplantation.
    Salama AD; Pusey CD
    Nat Clin Pract Nephrol; 2006 Apr; 2(4):221-30. PubMed ID: 16932428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Role of monoclonal antibodies in the treatment of immune-mediated kidney disease: the state of the art].
    Cravedi P
    G Ital Nefrol; 2012; 29(3):274-82; discussion 292. PubMed ID: 22718450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab and lupus--a promising pair?
    Ekö SL; van Vollenhoven RF
    Curr Rheumatol Rep; 2014; 16(9):444. PubMed ID: 25074032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A single dose of rituximab does not deplete B cells in secondary lymphoid organs but alters phenotype and function.
    Kamburova EG; Koenen HJ; Borgman KJ; ten Berge IJ; Joosten I; Hilbrands LB
    Am J Transplant; 2013 Jun; 13(6):1503-11. PubMed ID: 23570303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab in renal transplantation.
    Barnett AN; Hadjianastassiou VG; Mamode N
    Transpl Int; 2013 Jun; 26(6):563-75. PubMed ID: 23414100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New treatments for acute humoral rejection of kidney allografts.
    Venetz JP; Pascual M
    Expert Opin Investig Drugs; 2007 May; 16(5):625-33. PubMed ID: 17461736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of inflammatory immunologic disease 4. B cell targeting therapy using the anti-CD20 antibody rituximab in inflammatory autoimmune diseases.
    Tanaka Y
    Intern Med; 2007; 46(16):1313-5. PubMed ID: 17704614
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmacodynamics of rituximab in kidney allotransplantation.
    Genberg H; Hansson A; Wernerson A; Wennberg L; Tydén G
    Am J Transplant; 2006 Oct; 6(10):2418-28. PubMed ID: 16925569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab therapy in nephrotic syndrome: implications for patients' management.
    Sinha A; Bagga A
    Nat Rev Nephrol; 2013 Mar; 9(3):154-69. PubMed ID: 23338210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is B-cell depletion still a good strategy for treating immune thrombocytopenia?
    Godeau B; Stasi R
    Presse Med; 2014 Apr; 43(4 Pt 2):e79-85. PubMed ID: 24636845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.